Tecovirimat lacks potency against mpox, more studies show DENVER — Studies published in a medical journal and presented at a conference showed that tecovirimat did not increase clinical resolution of mpox and may contribute to antiviral resistance for people with HIV being treated for the disease.“The approval of tecovirimat for the treatment of smallpox is under the FDA Animal Rule and was based on efficacy data from preclinical lethal models of

🚨 Researchers are calling for better treatment options for #mpox atter two more studies have shown the limited benefits of the FDA-approved treatment #tecovirimat. Read more below ⤵️

vist.ly/4ty3p

Tecovirimat lacks potency against mpox, more studies show DENVER — Studies published in a medical journal and presented at a conference showed that tecovirimat did not increase clinical resolution of mpox and may contribute to antiviral resistance for people with HIV being treated for the disease.“The approval of tecovirimat for the treatment of smallpox is under the FDA Animal Rule and was based on efficacy data from preclinical lethal models of

‼️Two more studies assessing #tecovirimat as an #mpox treatment showed that the drug was not more effective than placebo in helping patients achieve clinical resolution.

More here: ⬇

vist.ly/4tvvt

Negative #clinicaltrials also matter. The STOMP study gives us clarity: #tecovirimat is safe but not effective for clade II #mpox. In #outbreaks, speed is critical but so is evidence. RCTs remain the gold standard for guiding real-world #publichealth decisions www.linkedin.com/posts/drmelv...

"This trial showed no evidence that #tecovirimat therapy shortened the time to clinical resolution, reduced pain, or increased viral clearance among adults with clade II #mpox."
⬇️

#Tecovirimat for the Treatment of #Mpox

#Tecovirimat for the Treatment of #Mpox, etidiohnew.blogspot.com/2026/02/teco...

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo | NEJM Tecovirimat is available for the treatment of mpox (formerly known as monkeypox) in Europe and the United States, on the basis of findings from efficacy studies in animals and safety evaluations in...

Not so good news about #tecovirimat for the treatment 9f clade I #mpox 💊

www.nejm.org/doi/full/10....

Mpox drug Tpoxx didn't speed lesion healing in clade 1 patients, trial shows

#Medsky🧪 #iDsky #immunosky #pedsky #pharmasky #publichealth The antiviral Rx #tecovirimat (Tpoxx) didn't accelerate lesion clearance in adults & children with clade 1 mpox @cidrap-asp.bsky.social

www.cidrap.umn.edu/mpox/mpox-dr...

Mpox antiviral treatment tecovirimat does not speed up lesion healing Mpox antiviral treatment tecovirimat does not speed up lesion healing The antiviral drug, Tecovirimat, has been made available for the treatment of mpox, but it was approved without data on how…

💉 #Tecovirimat is available for the treatment of mpox, but it was approved without data on how effective it actually is. Now, a trial has found it does not speed up lesion healing

i-Base graphic. The main text in red and dark blue, on a light blue blue background, reads: CROI 2025. Tecovirimat data confirmed. No benefit against mpox. Below, in white on a burnt orange background, text reads, San Francisco, California. 9th to 12th March. On top of this is a faint image of the Golden Gate Bridge. In the top left corner is a URL: I hyphen base dot info. In the top right corner is a box made of blue, yellow and red blocks. White text on it reads, HTB news. 2025.

#Tecovirimat has no benefit against #mpox:

i-base.info/htb/50631

Full results from the STOMP study have now been presented. They show that tecovirimat didn’t help treat or reduce pain from mpox.

#CROI2025 #IDsky #HIVsky #Medsky #DRC #GlobalHealth #GlobalCrisis

Colourful i-Base graphic. The main text reads: tecovirimat, no benefit against #mpox clade 1. Public data needed now. At the top is a URL: I dash base dot info. At the bottom it says, subscribe by email. A smaller, tilted square graphic on the right, reads: HTB news. 2025. HIV treatment, prevention, access, and more. The colours used in the image are teal, white, dark blue, sage green, light green, orange, yellow and red.

#Tecovirimat news:

Both #PALM007 and #STOMP studies closed early due to lack of benefit against #mpox.

i-base.info/htb/50006

Full data needs to be publicly available to help with the ongoing crisis.

#MpoxClade1 #GlobalHealth #PublicHealth #WHO @who.int

Structural insights into tecovirimat antiviral activity and poxvirus resistance - Nature Microbiology Tecovirimat forces dimerization of the poxvirus phospholipase F13 blocking virus spread. Clinical monkeypox virus strains resistant to tecovirimat show mutations in the F13 dimer interface.

Congrats to Pablo Guardado-Calvo and colleagues for the analysis of anti #monkeypox virus activity of #tecovirimat, which acts as a molecular glue, triggering dimerization of the #poxvirus F13 protein.
www.nature.com/articles/s41...

Mpox: a better understanding of tecovirimat resistance A virus originally found in animals, mpox – which causes the disease of the same name – is now circulating in humans. Since 2022, it has been the cause of major epidemics spreading outside endemic are...

🦠 Mpox: a better understanding of tecovirimat resistance
🔬 Scientists at the Institut Pasteur have uncovered how a viral enzyme interacts with tecovirimat. This breakthrough paves the way for new antiviral therapies.
📄 Study published in @naturemicrobiol.bsky.social #Mpox #tecovirimat

“If that would have lessened my symptoms, that would have been great...”: a qualitative study about the acceptability of tecovirimat as treatment for mpox - BMC Medicine Background Tecovirimat, an antiviral treatment for smallpox, was approved as a treatment for mpox by the European Medicines Agency in January 2022. Approval was granted under “exceptional circumstance...

#Medsky🧪 #IDsky #pharmasky #publichealth This exploratory study suggest that offering #tecovirimat vs emergency-licensed Tx) to people with #mpox is acceptable, although uptake will depend on knowledge of #mpox Tx options…

bmcmedicine.biomedcentral.com/articles/10....

In a ‘shocker’ decision, Japan approves mpox drug that failed in two efficacy trials Earlier European authorizations for tecovirimat are also being scrutinized in the face of fresh data

#MedSky🧪 #IDSky #episky #pharmasky #publichealth In a ‘shocker’ decision, 🇯🇵 approves #mpox rx that failed in 2 efficacy trials
Earlier EMA authorizations for #tecovirimat are also being scrutinized in the face of fresh data

www.science.org/content/arti... @science.org

NIH Study Finds Tecovirimat Safe, But Ineffective for Treating Mpox Interim findings from the STOMP trial reveal that tecovirimat does not significantly accelerate lesion resolution or reduce pain in mild to moderate mpox cases.

The NIH reports the STOMP trial found tecovirimat #TPOXX does not speed up lesion resolution or reduce pain in mild to moderate #mpox cases. #Tecovirimat #IDsky #Medsky #Monkeypox #PublicHealth

Read more: www.contagionlive.com/view/nih-stu...

NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain Study Examined Tecovirimat in Countries Affected by Global Clade II Mpox Outbreak.

NIH Study Finds #Tecovirimat Was Safe but Did Not Improve #Mpox Resolution or Pain
www.nih.gov/news-events/...

NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain Study Examined Tecovirimat in Countries Affected by Global Clade II Mpox Outbreak.

#MedSky🧪#IDsky #pharmasky #SkyRx #publichealth Study Examined #Tecovirimat in Countries Affected by Global Clade II Mpox Outbreak & Tecovirimat Was Safe but Did Not Improve #Mpox Resolution or Pain
www.nih.gov/news-events/...

NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain Tecovirimat was safe but did not reduce the time to lesion resolution or reduce pain among adults with mild to moderate clade II mpox and a low risk of severe disease in an international study.

The #NIAID-sponsored STOMP study found the antiviral drug #tecovirimat was safe but did not improve mpox resolution or pain among adults in countries affected by clade II #mpox #idsky #medsky
www.niaid.nih.gov/news-events/...

Mpox in DR Congo Not Resolved By Antiviral Drug Tecovirimat The antiviral drug tecovirimat did not reduce the duration of mpox lesions among people in the Democratic Republic of the Congo (DRC).

#MedSky🧪#IDSky #Publichealth Recently a #Clinicaltrial was conducted in DRC to test the effectiveness of the #antiviral drug #tecovirimat against the #monkeypox .Tecovirimat didn’t reduced the duration of #mpox lesions among children & adults with clade I mpox www.genengnews.com/topics/infec...

Neue Mpox-Variante breitet sich in Zentralafrika aus Eine neue Variante von Mpox breitet sich in Zentralafrika aus. Sie ist ansteckender als bisher - und in der Region fehlen die Mittel, um sie wirksam zu bekämpfen. Von Christopher Unger.

Es ist nicht ganz richtig, dass es keine Medikamente gegen #Mpox gibt. #Tecovirimat wurde aufgrund von Tierstudien, einschließlich der Wirkung gegen Mpox in Makaken, zur Behandlung vom #smallpox zugelassen. 1/